Medigene, bluebird bio Expand Cancer Immunotherapy Collaboration

Medigene has agreed to expand its nearly two-year-old, up-to-$1 billion-plus cancer immunotherapy collaboration with bluebird bio, saying today that the expansion could generate up to $509 million-plus more for Medigene, nearly all of that tied to developing two more T-cell receptor–modified T-cell (TCR-T) cancer immunotherapies.The companies have agreed to expand from four to six the number of target antigen/major histocompatibility complex (MHC) restriction combinations for the discovery